Islet Sciences Announces Participation at the 2012 American Transplant CongressSacramento BeeIslet Sciences will present an update on work with their xenotransplantation model for islet transplantation on June 5, 2012 at 5:30 PM ET. Islet Sciences is a…
Kids' Kidneys Can Work Well in Adult Recipients – Renal and Urology News
Kids' Kidneys Can Work Well in Adult RecipientsRenal and Urology NewsThe acute rejection rate at one year was 4%. The investigators concluded that transplant surgeons should be encouraged to use child donor kidneys, which frequently are discarded. …
Hélène Campbell 'dances' on Ellen DeGeneres show after double-lung transplant
Hélène Campbell, whose organ donation awareness campaign netted her an unexpected appearance three months ago on Ellen DeGeneres's daytime talk show, Ellen, was a return guest for the show's season finale.
Boston Scientific Secures FDA Approval For 32 MM, 38 MM Lengths – RTT News
Boston Scientific Secures FDA Approval For 32 MM, 38 MM LengthsRTT News(BSX: News ) said the US Food and Drug Administration, or FDA, has provided the company regulatory approval of 32 mm and 38 mm lengths for the PROMUS Element Plus Everolimus-Eluting…
Islet Sciences Announces Participation at the 2012 American Transplant Congress
NEW YORK, June 4, 2012 /PRNewswire/ — Islet Sciences, Inc., (OTCBB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation …
Boston Scientific Receives FDA Approval for 32 MM and 38 MM Lengths for PROMUS … – MarketWatch (press release)
Angioplasty.OrgBoston Scientific Receives FDA Approval for 32 MM and 38 MM Lengths for PROMUS …MarketWatch (press release)NATICK, Mass., June 4, 2012 /PRNewswire via COMTEX/ — The US Food and Drug Administration (FDA) has provided Boston Scientific …
ViroPharma initiates maribavir Phase 2 program for CMV infections
ViroPharma Incorporated today announced the initiation of a Phase 2 program to evaluate maribavir for the treatment of cytomegalovirus infections in transplant recipients.
From Earlier: Results from a Randomized Study of REVLIMID and Rituximab in … – Benzinga
From Earlier: Results from a Randomized Study of REVLIMID and Rituximab in …BenzingaCelgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced results from a randomized study comparing REVLIMID® (lenalidomide) plus ri…
ViroPharma announces initiation of clinical studies to evaluate maribavir
ViroPharma announced the initiation of a Phase 2 program to evaluate maribavir for the treatment of cytomegalovirus infections in transplant recipients. The planned program will consist of two independent …
ViroPharma Announces Initiation of Clinical Studies to Evaluate Maribavir for Treatment of Cytomegalovirus (CMV …
EXTON, Pa., June 4, 2012 /PRNewswire/ — ViroPharma Incorporated (NASDAQ: VPHM) today announced the initiation of a Phase 2 program to evaluate maribavir for the treatment of cytomegalovirus infections …